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Abstract
Background: Cardiac involvement of amyloidosis leads to left-ventricular (LV) wall thickening with progressive
heart failure requiring rehospitalization. Cardiovascular magnetic resonance (CMR) is a valuable tool to non-
invasively assess myocardial thickening as well as structural changes. Proton CMR spectroscopy (1H-CMRS)
additionally allows assessing metabolites including triglycerides (TG) and total creatine (CR). However, opposing
results exist regarding utilization of these metabolites in LV hypertrophy or thickening. Therefore, the aim of this
study was to measure metabolic alterations using 1H-CMRS in a group of patients with thickened myocardium
caused by cardiac amyloidosis.
Methods: 1H-CMRS was performed on a 1.5 T system (Achieva, Philips Healthcare, Best, The Netherlands) using a 5-
channel receive coil in 11 patients with cardiac amyloidosis (60.5 ± 11.4 years, 8 males) and 11 age- and gender-matched
controls (63.2 ± 8.9 years, 8 males). After cardiac morphology and function assessment, proton spectra from the
interventricular septum (IVS) were acquired using a double-triggered PRESS sequence. Post-processing was performed
using a customized reconstruction pipeline based on ReconFrame (GyroTools LLC, Zurich, Switzerland). Spectra were
fitted in jMRUI/AMARES and the ratios of triglyceride-to-water (TG/W) and total creatine-to-water (CR/W) were calculated.
Results: Besides an increased LV mass and a thickened IVS concomitant to the disease characteristics, patients
with cardiac amyloidosis presented with decreased global longitudinal (GLS) and circumferential (GCS) strain. LV
ejection fraction was preserved relative to controls (60.0 ± 13.2 vs. 66.1 ± 4.3%, p = 0.17). Myocardial TG/W ratios
were significantly decreased compared to controls (0.53 ± 0.23 vs. 0.80 ± 0.26%, p = 0.015). CR/W ratios did not
show a difference between both groups, but a higher standard deviation in patients with cardiac amyloidosis was
observed. Pearson correlation revealed a negative association between elevated LV mass and TG/W (R = − 0.59,
p = 0.004) as well as GCS (R = − 0.48, p = 0.025).
Conclusions: A decrease in myocardial TG/W can be detected in patients with cardiac amyloidosis alongside
impaired cardiac function with an association to the degree of myocardial thickening. Accordingly, 1H-CMRS may
provide an additional diagnostic tool to gauge progression of cardiac amyloidosis along with standard imaging
sequences.
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Background
Amyloidosis is a multisystemic disorder which is charac-
terized by extracellular deposition of misfolded amyloid
proteins leading to consecutive organ failure [1]. Cardiac
involvement is frequent. The most common types are
acquired or inherited transthyretin-related (ATTR) and
light-chain (AL) amyloidosis. Once affected, prognosis
and outcome of patients with cardiac amyloidosis deterio-
rates dependent on the subtype, hence requiring sufficient
diagnostic accuracy and follow-up strategies [2, 3]. Cur-
rently, definite diagnosis of cardiac amyloidosis is estab-
lished using either invasive tissue biopsy for all types or
technetium scintigraphy in ATTR amyloidosis respectively
[4, 5]. Cardiovascular magnetic resonance (CMR) is in-
creasingly used for screening purposes in patients with
suspected cardiac involvement of amyloidosis due to its
non-invasive nature and its potential to characterize dif-
ferent forms of amyloidosis [6, 7]. Typical cardiac manifes-
tations include myocardial thickening and diffuse late
gadolinium enhancement (LGE) resulting from expanded
extracellular space. However, the expression of cardiac
amyloidosis and its sub-forms can be heterogeneous and
the differentiation from other forms of myocardial thick-
ening may be challenging at early stages [1]. Besides the
detection of morphological and structural changes with
CMR, proton spectroscopy may offer additional insights
into the metabolism of healthy and diseased hearts [8, 9].
In particular, myocardial triglyceride (TG) and total creat-
ine (CR) content can be determined [9].
In the healthy human heart, β-oxidation of fatty acids
constitutes the major mechanism of energy production
that is subject to storage of TG [10]. In thickened
hearts, mainly in left-ventricular (LV) hypertrophy
(LVH), studies have provided controversial results
about TG utilization. In particular, myocardial TG was
found to be significantly reduced in hypertrophic car-
diomyopathy (HCM) while no changes were found in
LVH associated with Anderson-Fabry’s disease [11–13].
Potential metabolic alterations involved in myocardial
thickening due to cardiac amyloidosis have not been
studied in detail and previous histological and proton
spectroscopy studies present with contradictory results.
On the one hand, reduced TG utilization has been
found to associate with advanced stages of heart failure
and HCM while, on the other hand, histopathological
analyses revealed an association of fatty acids with
amyloid proteins [8, 14, 15].
Therefore, the objective of the present study was to as-
sess myocardial TG and additional CR content along with
functional parameters in a group of patients with cardiac
amyloidosis using CMR imaging and spectroscopy.
Methods
The study was conducted in accordance to the declaration
of Helsinki and its later amendments. Local ethics com-
mittee approval was obtained. All data acquired in this
study were handled anonymously and written informed
consent was obtained from each subject.
Study population
Eleven patients with cardiac amyloidosis (60.5 ± 11.4
years, 8 males, AL = 7, ATTR = 4) were recruited from
the interdisciplinary “Amyloidosis-Network” of the Uni-
versity Hospital Zurich. Cardiac involvement of systemic
amyloidosis was confirmed by endomyocardial biopsy, bi-
opsy of other tissue (fat, lips) or by imaging [4, 16]. Amyl-
oidosis patients as well as 11 age- and gender matched
controls (63.2 ± 8.9 years, 8 males) received CMR imaging
and spectroscopy at the University Hospital Zurich,
Switzerland. In addition, blood lipid- and N-terminal pro-
hormone of brain natriuretic peptide-levels (NT-proBNP)
were measured by acquiring blood samples. Subjects were
advised to adhere to a 3-h fasting period prior to the
CMR examination and scans were performed at after-
noon times.
Data acquisition
CMR imaging and spectroscopy was performed on a 1.5 T
system (Achieva, Philips Healthcare, Best, The
Netherlands) using a 5-channel phased array coil. After
scout and reference scans, anatomical and geometric data
were acquired using balanced steady-state free precession
(bSSFP) sequence in standard long-axis geometries (two-,
three- and four-chamber view) as well as in short-axis
view with full LV coverage from base to apex (repetition
time (TR)/echo time (TE) = 3.3 / 1.6 ms, flip angle =
60°, spatial resolution = 1.5 × 1.5 × 8 mm3, 50 phases, 2
slices per breathhold).
In cases with an estimated glomerular filtration rate
(eGFR) > 35 mL/min and informed consent of the sub-
ject, a gadolinium-based contrast agent (Gadovist,
Bayer Healthcare, Berlin, Germany) was injected for
LGE imaging to visualize fibrosis and scarring. Ethical
approval constrains only allowed the administration of
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contrast agent in amyloidosis patients. All patients were
eligible to receive gadolinium. After a period of 10 min,
a 3-dimensional gradient spoiled turbo fast-field echo
sequence with a non-selective 180° inversion pre-pulse
was performed at end diastole (TR/TE = 3.3/1.6 ms, flip
angle = 15°, spatial resolution = 1.6 × 1.6 × 5 mm3, ad-
justed inversion delay, one breath-hold for each ana-
tomical location) in the same anatomical location as
the bSSFP scans [17].
Spectroscopy
Spectroscopy data were acquired after anatomical cine im-
aging and prior to contrast agent injection. Cine imaging
in four-chamber and short-axis views were repeated with
navigator gating on the diaphragm for subsequent plan-
ning of the spectroscopic voxel and to account for poten-
tial subject movement during the scan session. Prior to
the acquisition of spectroscopy data, iterative volume
shimming was performed over a volume of 15 × 25 × 45
mm3 during a single breathhold. Thereafter, voxels of 7–8
mL (10 × 20 × 35–40mm3) were positioned in the inter-
ventricular septum (IVS) and proton spectra were re-
corded using a PRESS (point-resolved spectroscopy)
sequence in systole with optimized spoilers (Fig. 1) [18].
Spectroscopic data acquisition was double-triggered
using electrocardiogram (ECG) triggering and pencil
beam navigator-based respiratory gating on the dia-
phragm with a gating window of 4 mm. Water suppres-
sion was achieved by chemical shift selective saturation
(CHESS) (excitation bandwidth 100 Hz) [19]. A total of
96 averages with water suppression and 16 averages
without water suppression were recorded at a spectral
bandwidth of 2000 Hz (1024 samples) and a minimum
TR of 2000 ms (TE = 22 ms, flip angle = 90°).
Post-processing
Functional and geometric parameter assessment based
on imaging data was achieved using commercial post-
processing software (IntelliSpace Portal, Philips, Best,
The Netherlands). The bSSFP imaging data were used
to measure the IVS at maximum extension in end dia-
stole, LV and right ventricular (RV) end-diastolic volume
(LVEDV/RVEDV), left ventricular end-diastolic diameter
(LVEDD), left and right ventricular ejection fraction
(LVEF/RVEF), stroke volume (SV), and LVM indexed to
body surface area (LVMi).
LV strain and strain rate analysis was performed
using feature tracking analysis (Image-Arena VA Ver-
sion 4.6 and 2D Cardiac Performance Analysis MR
Version 4, TomTec Imaging Systems, Unterschleis-
sheim, Germany). The bSSFP images were used to
manually draw endocardial contours followed by
software-driven automatic tracking. End-systolic global
longitudinal (GLS) and circumferential strain (GCS)
as well as peak diastolic longitudinal and circumferen-
tial strain rate were extracted.
Spectroscopy data were first reconstructed in MATLAB
(The Mathworks, Natick, Massachusetts, USA) using a
customized reconstruction pipeline based on ReconFrame
(GyroTools LLC, Zurich, Switzerland) as illustrated in
Fig. 2. After noise decorrelation, a singular value de-
composition approach (SVD) was used for the combin-
ation of all five individual coil channels. Weights
estimated from the water spectra were used for the cal-
culation of water-unsuppressed and water-suppressed
signals [20, 21]. Following this step, individual averages
were phase-corrected. For non-water suppressed spectra,
phasing was based on the water peak whereas for
water-suppressed spectra, phasing was based on the peak
ba
Fig. 1 Position of the 1H-CMRS voxel within the IVS of a patient with cardiac amyloidosis (a) and of a normal control (b). IVS, interventricular
septum; 1H-CMRS, Proton CMR spectroscopy
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at 1.3 ppm for TG and on the peak at 3.01 ppm for CR.
Afterwards, averaging was conducted.
Reconstructed and averaged spectra were analysed in
jMRUI/AMARES (version 5.2) [22] Water-unsuppressed
and water-suppressed spectra were time-domain fitted
using Lorentzian line shapes after first-order phase correc-
tion. A Hankel-Lanczos Singular Value Decomposition
(HLSVD) approach was used to filter out the residual
water peak and a total of six resonances were fitted to the
water-suppressed spectra: (1) TG at 0.9, 1.3 and 2.1 ppm,
(2) CR at 3.01 ppm, (3) trimethylammonium (TMA) at
3.2 ppm and (4) the residual water at 4.7 ppm. The max-
imum linewidth of all resonances was limited by soft con-
straints to 0.75 ppm and relative chemical shifts were used
as fixed boundary conditions.
For the calculation of triglyceride- and creatine-to-water
ratios (TG/W and CR/W), data were first corrected for
longitudinal and transverse relaxation by using T1 = 970
ms and T2 = 40ms for myocardial water, T1 = 280ms and
T2 = 80ms for myocardial TG, and T1 = 1480ms and
T2 = 135ms for CR [21, 23]. The TG/W ratio was then
calculated as the sum of the fitted TG resonances at 0.9
and 1.3 ppm divided by the fitted water. The CR/W ratio
was calculated from the CR resonance at 3.01 ppm divided
by the fitted water signal.
The amount of fibrosis as percentage of LVMi was
calculated semi-automatically by manually applying epi-
and endocardial contours to the short-axis LGE images
for every slice. Then, the amount of fibrosis was calculated
using a full-width-at-half-maximum (FWHM) approach
as previously described [24].
Statistical analysis
Statistical analyses were conducted using SPSS (version
24.0, International Business Machines, Armonk, New
York, US). Continuous variables are expressed as mean ±
standard deviation (SD). Categorical variables are reported
as percentages. After testing for normal distribution using
a Kolmogorov-Smirnov test, data between groups were
compared using a 2-sided unpaired Student’s t-test for
normally distributed data and a non-parametric Mann-
Whitney U-tests for not normally distributed data. Fisher’s
exact t-test was used to examine significant differences
between nominal classifications. Bivariate Pearson correl-
ation analysis was conducted to analyze relationships be-
tween different CMR parameter including 1H-CMRS
results. P-values below 0.05 were considered as statistically
significant.
Results
Study population and clinical characteristics
Cardiovascular comorbidities, age- and sex were not sig-
nificantly different between amyloidosis patients and the
control group. Biochemical analyses revealed no differ-
ences in blood lipid levels between the groups (Table 1).
NT-proBNP of amyloidosis patients was elevated ac-
cording to recent heart failure guidelines [25].
Imaging
Baseline CMR parameters of amyloidosis patients and
controls are summarized in Table 2. Amyloidosis pa-
tients showed significantly elevated IVS and LVMi. LVEF
as one surrogate for myocardial systolic function did not
Fig. 2 Flow chart of CMR imaging and spectroscopy as well as processing pipeline for spectroscopy data. CR, Creatine; Gd-CA, gadolinium based
contrast agent; LGE, late gadolinium enhancement; CMRS, cardiovascular magnetic resonance spectroscopy; bSSFP, balanced steady state free
precession; PRESS, point-resolved spectroscopy; TG, triglycerides
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show a significant alteration, but GLS and GCS were
significantly reduced compared to controls (p < 0.001 for
GLS and p = 0.007 for GCS). Circumferential peak longi-
tudinal strain rate as a surrogate for diastolic function
was decreased in amyloidosis patients (p = 0.019). Fibro-
sis extent in the amyloidosis patients ranged from 2 to
74% (mean: 36.1 ± 27.1%) of the LV wall.
Apart from an elevated LVEDV (AL vs. ATTR: 119.4 ±
20.1 vs. 148.8 ± 14.9, p = 0.032) and a trend towards a de-
crease in GLS and GCS (AL vs. ATTR: GLS = − 21.9 ± 4.5
vs. -15.8 ± 5.7%, p = 0.08; GCS = − 32.4 ± 5.4 vs. -25.3 ±
4.7%, p = 0.058) for the ATTR-type, there was no signifi-
cant difference between both groups.
At the time of the CMR exam, 4 amyloidosis patients
had already received autologous stem cell transplant-
ation. Those patients showed improved GCS and cir-
cumferential strain rate in comparisons to the medically
treated patients (GCS = − 34.5 ± 5.0 vs. -27.2 ± 5.2%,
p = 0.048; circumferential strain rate = 1.5 ± 0.3 vs. 1.2
± 0.2 s− 1, p = 0.06) with no statistical significance com-
pared to the normal controls.
Spectroscopy
Spectroscopic data revealed decreased TG/W ratios of
0.53 ± 0.23% for the cardiac amyloidosis group in com-
parison to the control group (0.80 ± 0.26%, p = 0.015)
(Figs. 3 & 4). Myocardial CR/W ratios did not show sig-
nificant differences between both groups, although amyl-
oidosis patients exhibited a larger variation by means of
SD (amyloidosis vs controls: 0.09 ± 0.08 vs. 0.09 ± 0.03%).
Dividing amyloidosis patients according to their type of
amyloidosis or according to their previous treatment
(+/− stem cell therapy), no differences in TG/W and
CR/W ratios could be detected.
Correlation analysis
Figure 5 shows bivariate Pearson’s correlation between
imaging parameters of LV-hypertrophy or function and
TG/W ratios. Decreasing TG/W ratios with increasing
LVMi and IVS were found (IVS: R = − 0.46, p = 0.033;
LVMi: R = − 0.59, p = 0.004).
Comparing myocardial functional LV parameters,
there was no correlation between TG/W and LVEF, but
there was for TG/W and GLS (R = − 0.46, p = 0.033) and
GCS (R = − 0.48, p = 0.025). Fibrosis, age, NT-proBNP
and blood lipid levels did not show any correlations. CR/
W did not correlate to any of those parameters.
Discussion
In the present study, CMR spectroscopy identified re-
duced TG/W ratios, but no change of CR/W in patients
Table 1 Demographic and clinical baseline characteristics
Amyloidosis
(n = 11)
Controls
(n = 11)
P-value
Age (years) 60.5 ± 11.4 62.9 ± 8.9 0.57
Male (%) 8 (73) 8 (73) 1.0
BMI (g/m2) 24.3 ± 2.9 24.2 ± 4.6 0.94
AL-Amyloidosis 7 (64) – –
Disease duration (years) 2.19 ± 2.1 – –
Comorbidities
Diabetes, n(%) 1 (9) 0 (0) 0.31
Hypertension, n(%) 4 (36) 5 (45) 0.66
CAD, n(%) 0 (0) 0 (0) 1.0
Previous stroke, n(%) 1 (9) 0 (0) 0.31
Class NYHA III-IV n(%) 2 (18) 0 (0) 0.14
Biochemical
Cholesterol (mmol/L) 5.9 ± 3.2 5.6 ± 1.0 0.794
HDL (mmol/L) 1.3 ± 0.5 1.5 ± 0.4 0.187
Non-HDL (mmol/L) 4.5 ± 3.4 4.0 ± 1.0 0.664
LDL (mmol/L) 2.7 ± 1.2 3.3 ± 0.8 0.234
Triglycerides (mmol/L) 2.5 ± 2.9 1.7 ± 0.9 0.358
NT-proBNP (ng/L) 1287 ± 1304 – –
Creatinine (μg/dL) 110 ± 33.9 – –
Treatment
Stem cell transplantation 4 (36) – –
Chemotherapy 7 (64) – –
Green tea 3 (27) – –
AL amyloid light-chain, BMI body mass index, CAD coronary artery disease, GFR
glomerular filtration rate, HDL high density lipoprotein, LDL low density
lipoprotein, NYHA New York Heart Association, NT-proBNP N-terminal
prohormone of brain natriuretic peptide-levels
Table 2 Baseline CMR characteristics of patients and controls
Amyloidosis Controls P-value
LVEF (%) 60.0 ± 13.2 66.1 ± 4.3 0.170
IVS (mm) 18.0 ± 4.6 8.0 ± 1.5 < 0.001
LVMi(g/m2) 85.2 ± 25.1 45.0 ± 8.7 < 0.001
LVEDV (mL) 130.1 ± 23.0 126.9 ± 34.0 0.8
LVEDD (mm) 46.2 ± 3.5 46.9 ± 4.6 0.678
SV (mL) 76.7 ± 16.3 84.5 ± 20.2 0.331
RVEF (%) 64.5 ± 9.5 62.8 ± 5.0 0.604
RVEDV (mL) 112.0 ± 30.5 130.1 ± 29.3 0.171
GLS (%) −19.7 ± 5.6 −31.1 ± 5.5 < 0.001
GCS (%) −29.8 ± 6.1 −36.2 ± 3.3 0.007
Long SRe 1.7 ± 0.5 1.4 ± 0.4 0.076
Circ SRe 1.3 ± 0.3 1.7 ± 0.4 0.019
Circ circumferential, GLS global longitudinal strain, GCS global circumferential
strain, IVS interventricular septum, Long longitudinal, LVEDD left ventricular
end-diastolic diameter, LVEDV/RVEDV left/right ventricular end-diastolic
volume, LVEF/RVEF left/right ventricular ejection fraction, LVMi left ventricular
mass indexed to body surface area, SRe strain rate, SV stroke volume
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with cardiac amyloidosis when compared to age-matched
controls. TG/W was negatively correlated with the sever-
ity of LV thickening and LV strain, but not with LVEF.
The reduced myocardial TG/W ratios in the myocar-
dium of patients with amyloidosis are in line with previ-
ous studies describing reduced TG content in patients
with HCM [8, 11]. Fatty acids (FA) are the major source
for myocardial energy in the healthy heart [9, 10]. How-
ever myocardial FA oxidation is impaired in heart fail-
ure, which in turn, may also trigger myocardial TG
accumulation [8, 26, 27]. Recent literature and the
current findings indicate that the pathophysiology of
myocardial thickening and/or LVH may play an add-
itional role in myocardial TG accumulation. In HCM,
decreasing TG content has been reported [11]. In sec-
ondary LVH (e.g. valvular or Anderson-Fabry’s disease)
different results can be found depending on the patho-
genesis [13, 28]. In mild hypertrophy caused by competi-
tive sports, TG content was preserved [28]. Surprisingly,
Anderson-Fabry’s disease that presents with an accumu-
lation of sphingolipids did not associate with an in-
creased TG content [13].
a b
Fig. 3 Mean and SD of TG/W and CR/W ratios in patients with amyloidosis compared to an age- and BMI-matched normal control group. TG/W,
triglyceride-to-water; Cr/W, creatine-to-water; SD, standard deviation
Fig. 4 Exemplary spectra in a patient with amyloidosis and in a control. TG/W, triglyceride-to-water; CR/W, creatine-to-water; ppm, part
per million
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In the general context, CMR spectroscopy studies suggest
that accumulation of lipids in LVH and heart failure is most
pronounced when associated with obesity, overweight or
diabetes [29, 30]. Only one subject of the present study
group suffered from diabetes. Indeed, the person with
cardiac amyloidosis suffering from diabetes and add-
itional overweight (body mass index (BMI) > 25 kg/m2)
exhibited one of the highest TG/W ratios within the
amyloidosis cohort. This indicates that these two risk
factors might offset the reduction in TG/W ratios. TG/
W ratios did not correlate with BMI, blood lipid levels
or age in the present study, suggesting that TG/W ra-
tios may associate with other factors, such as the accu-
mulation of amyloid proteins. This is indicated by the
negative relationship between TG content and the se-
verity of the thickened myocardium (Fig. 5) and a
known histologic correlation of amyloid and the
amount of fibrosis [31].
Amyloid proteins of any type mainly deposit within
the myocardial interstitium and extend the extracellular
volume which may hamper extramyocellular TG depos-
ition [32, 33]. So far, the direct influence of amyloid on
TG is unknown, but an increasing effect on the
T1-values of the global myocardium has already been de-
scribed [3]. As a consequence of the prolonged T1-values
of tissue water, partial saturation increases using PRESS
with a fixed TR of 2000 ms. Correcting the water signal
for those T1-values would increase the signal by approxi-
mately 10% and therefore the TG/W ratio would further
decrease below the value stated above. Another possible
mechanism may relate to the myocytotoxic effects of
circulating amyloid light chains and their influence on
mitochondrial function, i.e. the β-oxidation of free fatty
acids [34–36]. This interaction causes oxidative stress of
the cell leading to the toxic effects in proteins, lipids,
DNA and inflammatory processes [27]. Not only amyloid
a b
c d
Fig. 5 Pearson’s correlation between TG/W ratios and (a) IVS and (b) LVMi, (c) GLS as well as (d) GCS. GCS, global circumferential strain; GLS,
global longitudinal strain; IVS, interventricular septum; LVMi, left-ventricular mass indexed to body surface area; TG/W, triglyceride-to-water
Gastl et al. Journal of Cardiovascular Magnetic Resonance           (2019) 21:10 Page 7 of 10
light chains interact with free FAs, but also the amyloid of
Alzheimer’s disease that reduces unsaturated fatty acids in
certain parts of the brain known to cause dementia [37].
However, further research of the exact mechanism of
metabolic alterations in cardiac amyloidosis has to be
pursued.
Results in the age-matched controls were in line with
previous literature [38, 39]. To address diurnal changes
of TG/W, subjects and patients were scanned during
afternoon hours and with a prior fasting period of about
3 h [40].
No mean difference of CR/W could be detected be-
tween patients and controls. However, SD of myocardial
CR was higher in the amyloidosis group potentially due
to different disease states of the patients [41, 42]. In con-
trast to previous studies, no correlation between CR/W
ratios and LV function parameters could be detected [10,
43]. It should, however, be noted that fitting of CR peaks
is challenging due to their low signal and hence results
may be confounded by fitting errors [9].
Although 1H-CMRS has not yet found its way into
clinical routine due to technical demands and the still
time-consuming scan, 1H-CMRS may add clinical value
by detecting metabolic changes in the course of develop-
ing cardiac amyloidosis. Considering the current pro-
gress regarding scan time reduction and ease-of-use of
1H-CMRS, there is the potential to integrate the method
into standard imaging workflows.
Besides LGE, parametric imaging techniques including
T1 and extracellular volume (ECV) mapping have been
used in cardiac amyloidosis to distinguish different amyl-
oidosis types [44, 45]. Both LGE and ECV mapping re-
quire gadolinium injection which excludes patients with
severe renal insufficiency. In these patients, expansion of
ECV may be identified through changes in the triglycer-
ide levels using 1H-CMRS. Moreover, modulation of
TG/W values may point directly to myocytotoxic effects
of circulating amyloid chains which potentially contribute
to ECV expansion as measured with T1/ECV mapping
[27]. These insights, however, remain to be established
through larger studies in the future.
Limitations
The present sample size was relatively small due to the
technical demands of the study. Subject numbers were
however comparable to previous studies assessing myo-
cardial metabolism in heart failure [11, 28]. Assuming de-
creased myocardial TG/W according to literature, we
sought to identify an effect in comparison to normal con-
trols with a statistical power of 90% and type I error of less
than 5%, resulting in an estimated sample size of 10 per
group [11].
As cardiac amyloidosis had already been confirmed in
all patients at the time of CMR, we did not perform
myocardial biopsies to quantify myocardial TG content
and to differentiate intramyocellular (IMCL) and extra-
myocellular lipids (EMCL). The differentiation of IMCL
and EMCL may help to understand the mechanism of the
TG/W reduction in cardiac amyloidosis and whether it is
caused by expanded extracellular space or by a reduced
metabolism of myocytes. Although recent work has shown
feasibility to quantify IMCL and EMCL in the human
heart using spectroscopy, the present method could not
reliably differentiate between the different pools [46].
Conclusions
Myocardial TG/W decreases in cardiac amyloidosis and
is associated with the severity of myocardial thickening
and systolic dysfunction, independent of age, BMI and
blood lipid levels.CMR proton spectroscopy may provide
additional information to gauge progression of cardiac
amyloidosis.
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